Effect of freezing on recombinant hepatitis E vaccine

References

• Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, Reyes GR. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology. 1991;185:120–31. doi:10.1016/0042-6822(91)90760-9.
   PubMed Web of Science ®Google Scholar
• Riveiro-Barciela M, Rodríguez-Frías F, Buti M. Hepatitis E virus: new faces of an old infection. Ann Hepatol. 2013;12(6):861. doi:10.1016/S1665-2681(19)31290-6.
   PubMed Web of Science ®Google Scholar
• Krain LJ, Nelson KE, Labrique AB. Host immune status and response to hepatitis E virus infection. Clin Microbiol Rev. 2014;27:139–65.
   PubMed Web of Science ®Google Scholar
• Aggarwal R. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review. Geneva (Switzerland): World Health Organization; 2010.
   Google Scholar
• Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med. 1981;70:252–55. doi:10.1016/0002-9343(81)90758-0.
   PubMed Web of Science ®Google Scholar
• Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet. 2004;85:240–44. doi:10.1016/j.ijgo.2003.11.018.
   PubMed Web of Science ®Google Scholar
• Proffitt A. First HEV vaccine approved. Nat Biotechnol. 2012;30(4):300. doi:10.1038/nbt0412-300a.
   PubMedGoogle Scholar
• Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH. A bacterially expressed particulate hepatitis e vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine. 2005;23(22):2893–901. doi:10.1016/j.vaccine.2004.11.064.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902. doi:10.1016/S0140-6736(10)61030-6.
   PubMed Web of Science ®Google Scholar
• Das MK, Arora NK, Mathew T, Vyas B, Sindhu M, Yadav A. Temperature integrity and exposure to freezing temperature during vaccine transfer under the universal immunization program in Three States of India. Indian J Publ. Health. 2019;63(2):139–42. doi:10.4103/ijph.IJPH_123_18.
   PubMed Web of Science ®Google Scholar
• Lloyd J, Lydon P, Ouhichi R, Zaffran M. Reducing the loss of vaccines from accidental freezing in the cold chain: the experience of continuous temperature monitoring in tunisia. Vaccine. 2015;33(7):902–07. doi:10.1016/j.vaccine.2014.10.080.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). The effects of freezing on the appearance, potency, and toxicity of adsorbed and unadsorbed DTP vaccines. Wkly Epidemiol Rec. 1980;55:385–92.
   Google Scholar
• Dietz V, Ga1azka A, van Loon F, Cochi S. Factors affecting the immunogenicity and potency of tetanus toxoid: implications for the elimination of neonatal and non-neonatal tetanus as public health problems. Bull World Health Organ. 1997;75:81–93.
   PubMed Web of Science ®Google Scholar
• Galazka A, Milstien J, Zaffran M. Thermostability of vaccines. Geneva (Switzerland): World Health Organization; 1998. [WHO document WHO/GPV/98.07].
   Google Scholar
• Zhan Y, Li M, Yang F, Li Y, Zheng Z, Zhang X, Lin Q, Wang Y, Li S, Xia N. Comparable quality attributes of hepatitis e vaccine antigen with and without adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother. 2015;11(5):1129–39. doi:10.1080/21645515.2015.1009343.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gu Y, Ge SX, Li SW, He ZQ, Huang GY, Zhuang H, Ng MH, Xia NS. Analysis of hepatitis e virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine. 2005;23(22):0–2892. doi:10.1016/j.vaccine.2004.11.065.
   Web of Science ®Google Scholar
• Zhang F, Li X, Li Z, Harrison TJ, Chong H, Qiao S, Huang W, Zhang H, Zhuang H, Wang Y. Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E. J Med Virol. 2010;78(11):1441–48. doi:10.1002/jmv.20717.
   Google Scholar
• Gu Y, Tang X, Zhang X, Song C, Sivaraman J. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 2015;25(5):604–20. doi:10.1038/cr.2015.34.
   PubMed Web of Science ®Google Scholar
• Zhao M, Li XJ, Tang ZM, Yang F, Wang SL, Cai W, Zhang K, Xia NS, Zheng ZZ. A comprehensive study of neutralizing antigenic sites on the hepatitis E virus (HEV) capsid by constructing, clustering, and characterizing a tool box. J Biol Chem. 2015;290(32):19910–22. doi:10.1074/jbc.M115.649764.
   PubMed Web of Science ®Google Scholar
• Milstien JB, Galazka AM, Kartoglu Ü, Zaffran M. Temperature sensitivity of vaccines. Geneva (Switzerland): World Health Organization; 2006. https://apps.who.int/iris/handle/10665/69387.
   Google Scholar
• European Pharmacopoeia Edition 9.0,2.5.33, Total protein.
   Google Scholar
• Zhao C, Geng Y, Harrison TJ, Huang W, Song A, Wang Y. Evaluation of an antigen-capture EIA for the diagnosis of hepatitis e virus infection. J Viral Hepat. 2015;22(11):957–63. doi:10.1111/jvh.12397.
   PubMed Web of Science ®Google Scholar
• Reed LJ. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27(3). doi:10.1093/oxfordjournals.aje.a118408.
   Google Scholar
• Wu X, Chen P, Lin H, Su Y, Hao X, Cao F, Li L, Zhu F, Liang Z. Dynamics of 8G12 competitive antibody in “prime-boost” vaccination of hepatitis e vaccine. Hum Vaccin Immunother. 2017;13(6):1. doi:10.1080/21645515.2017.1291105.
   Web of Science ®Google Scholar
• White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr, Maes EF, Oberste MS. Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. Biologicals. 2018;53:30–38. doi:10.1016/j.biologicals.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Kartoglu U, Ozguler NK, Wolfson LJ, Kurza˛tkowski W. Validation of the shake test for detecting freeze damage to adsorbed vaccines. Bull World Health Organ. 2010;88:624–31. doi:10.2471/BLT.08.056879.
   PubMed Web of Science ®Google Scholar
• Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV igg kits and a re-evaluation of anti-HEV igg seroprevalence data in developed countries. J Med Virol. 2010;82(5):799–805. doi:10.1002/jmv.v82:5.
   PubMed Web of Science ®Google Scholar
• Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. The development of a recombinant hepatitis e vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908–14. doi:10.1080/21645515.2015.1008870.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX. Randomized-controlled phase ii clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine. 2009;27(12):1869–74. doi:10.1016/j.vaccine.2008.12.061.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q. Long-term efficacy of a hepatitis e vaccine. N Engl J Med. 2015;372(15):914–22. doi:10.1056/NEJMoa1406011.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis e vaccine: who position paper, May 2015–recommendations. Vaccine. 2015;34:3.
   Web of Science ®Google Scholar
• Yakum MN, Ateudjieu J, Pélagie FR, Walter EA, Watcho P. Factors associated with the exposure of vaccines to adverse temperature conditions: the case of north west region, Cameroon. BMC Res Notes. 2015. doi:10.1186/s13104-015-1257-y.
   Google Scholar
• Organization, WH, Fund, UNC. How to monitor temperatures in the vaccine supply chain. In: International joint conference on artificial intelligence. San Francisco (CA): Morgan Kau-fmann Pubishers Inc.; 2015. p. 948–50.
   Google Scholar
• Davaalkham D, Ojima T, Wiersma S, Lkhagvasuren T, Nymadawa P, Uehara R, Watanabe M, Oki I, Nakamura Y. Evidence based public health policy and practice: administration of hepatitis b vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J Epidemiol Community Health. 2007;61(7):578–84. doi:10.1136/jech.2006.051375.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J. Real-time stability of a hepatitis E vaccine (Hecolin ®) demonstrated with potency assays and multifaceted physicochemical methods. Vaccine. 2016;34(48):5871–77. doi:10.1016/j.vaccine.2016.10.045.
   PubMed Web of Science ®Google Scholar
• Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, Guy M, Kristensen DD, Braun LJ. Characterization of the freeze sensitivity of a hepatitis b vaccine. Hum Vaccin. 2009;5(1):26–32. doi:10.4161/hv.5.1.6494.
   PubMed Web of Science ®Google Scholar
• Kurzątkowski W, Kartoğlu Ü, Staniszewska M, Górska P, Krause A, Wysocki MJ. Structural damages in adsorbed vaccines affected by freezing. Biologicals. 2013;41(2):71–76. doi:10.1016/j.biologicals.2011.10.011.
   PubMed Web of Science ®Google Scholar
• Ho MM, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R, Corbel MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine. 2002;20(29):3509–22.
   PubMed Web of Science ®Google Scholar
• Kanra G, Viviani S, Yurdakök K, Ozmert E, Anemona A, Yalçin S, Demiralp O, Bilgili N, Kara A, Cengiz AB. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. Pediatr Int. 2010;45(3):314–18. doi:10.1046/j.1442-200X.2003.01706.x.
   Google Scholar
• Dimayuga R, Scheifele D, Bell A. Effects of freezing on DPT and DPT-IPV vaccines, adsorbed. Can Commun Dis Rep. 1995;21:101–03.
   PubMedGoogle Scholar
• Sitrin RD, Zhao Q, Potter CS, Carragher B, Washabaugh MW. Recombinant virus-like particle protein vaccines. In: Nunnally B, Turula V, Sitrin R, editors. Vaccine analysis: strategies, principles, and control. Berlin, Heidelberg: Springer; 2015. p. 81–112. https://doi.org/10.1007/978-3-662-45024-6_3.
   Google Scholar
• Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R. Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and gardasil vaccine samples. Hum Vaccin. 2005;1(5):191–97. doi:10.4161/hv.1.5.2126.
   PubMed Web of Science ®Google Scholar
• Rimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, Sauzeat E, Fournier JG, Clayette P, Siegrist CA. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine. 2004;22(23):3127–35. doi:10.1016/j.vaccine.2004.01.061.
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol. 2007;178(8):5271. doi:10.4049/jimmunol.178.8.5271.
   PubMed Web of Science ®Google Scholar
• Floris I, Appel K, Rose T, Lejeune B. LARTH®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion. J Inflam Res. 2018;11:397–460. doi:10.2147/JIR.S174326.
   PubMed Web of Science ®Google Scholar
• Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine. 2007;25(20):0–3986. doi:10.1016/j.vaccine.2007.02.052.
   Web of Science ®Google Scholar
• Braun LJ, Tyagi A, Perkins S, Carpenter J, Sylvester D, Guy M, Kristensen D, Chen D. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine. 2009;27(1):72–79. doi:10.1016/j.vaccine.2008.10.027.
   PubMed Web of Science ®Google Scholar
• Solanki VA, Jain NK, Roy I. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation. Int J Pharm. 2012;423(2):297–302. doi:10.1016/j.ijpharm.2011.11.039.
   PubMedGoogle Scholar
• Fortpied J, Wauters F, Rochart C, Hermand P, Hoet B, Moniotte N, Vojtek I. Stability of an aluminum salt-adjuvanted protein d-conjugated pneumococcal vaccine after exposure to subzero temperatures. Hum Vaccin Immunother. 2018;14(5):1243–50. doi:10.1080/21645515.2017.1421878.
   PubMed Web of Science ®Google Scholar
• Boros CA, Hanlon M, Gold MS, Roberton DM. Storage at −3 °C for 24 h alters the immunogenicity of pertussis vaccines. Vaccine. 2001;19(25–26):3537–42. doi:10.1016/S0264-410X(01)00063-9.
   PubMed Web of Science ®Google Scholar
• Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide–CRM (197) conjugate vaccines. Vaccine. 2001;19(23–24):3189–200. doi:10.1016/S0264-410X(01)00024-X.
   PubMed Web of Science ®Google Scholar
• Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine. 1999;18(1–2):3–17. 27. doi:10.1016/S0264-410X(99)00149-8.
   PubMed Web of Science ®Google Scholar